Phase 4
Completed N=50
Carbetocin on Myocardial Repolarization Dynamics in Obstetrics Study
Cardiac Arrythmias
Source: ClinicalTrials.gov NCT03716076 ↗
Enrolled (actual)
50
Serious AEs
0.0%
Results posted
May 2021
Primary outcomePrimary: Tp-e — 69.5; 74.7 milliseconds
◆ Published Evidence
Emerging
10citations · ~2 / year
The Effect of Carbetocin Dose on Transmural Dispersion of Myocardial Repolarization in Healthy Parturients Scheduled for Elective Cesarean Delivery Under Spinal Anesthesia: A Prospective, Randomized Clinical Trial.
Summary
Relationship between carbetocin dose on transmural dispersion of repolarization (TDR).
Linked Publications
-
The Effect of Carbetocin Dose on Transmural Dispersion of Myocardial Repolarization in Healthy Parturients Scheduled for Elective Cesarean Delivery Under Spinal Anesthesia: A Prospective, Randomized Clinical Trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Tp-e |
69.5; 74.7 | — |
| SECONDARY Arrhythmia |
0; 0 | — |
| SECONDARY QTc at 5 Min |
435.1; 434.2 | — |
| SECONDARY QTc 10 Min |
431.6; 431.9 | — |
| SECONDARY QTc 5 Min Spinal |
409.4; 413.6 | — |
| SECONDARY Tp-e 5 Min Post-spinal |
69.5; 70.9 | — |
| SECONDARY Tp-e at 10 Min |
69.4; 71.8 | — |
Eligibility Criteria
Inclusion Criteria
- Pregnant patients ≥ 36 weeks gestation, for elective Cesarean delivery under neuraxial anesthesia
- American Society of Anesthesiologists (ASA) class 2
- Patients ≥ 19 years of age
Exclusion Criteria
- Long QT syndrome
- Cardiac disease or rhythm abnormalities
- Family history of long QT syndrome or abnormal cardiac conduction
- Currently taking medication that is known to prolong the QT interval
- Women who are high risk for uterine atony as outlined in SOGC
- Known allergic reaction or hypersensitivity to Carbetocin or any other oxytocin homologue
- Patients who are unable to give informed consent because of a language barrier as the study team only speaks English and will be unable to complete consent process and study procedure appropriately.
Data sourced from ClinicalTrials.gov (NCT03716076) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.